Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-02-14 3:00 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | Cormorant Asset Management, LP | 1,428,598 9.9% | 1,428,598 (New Position) | View |
| 2022-02-11 07:20 am Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | Woodline Partners LP | 685,273 4.8% | 685,273 (New Position) | View |
| 2022-02-10 09:01 am Unchanged | 13G | Eledon Pharmaceuticals, Inc. ELDN | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 0% | 0 (Unchanged) | View |
| 2022-02-09 09:11 am Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | FMR LLC | 504,371 3.525% | 504,371 (New Position) | View |
| 2022-01-28 4:35 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | BIOTECHNOLOGY VALUE FUND L P | 2,326,710 16.9% | 878,690 (+60.68%) | View |
| 2022-01-26 4:27 pm Sale | 13G | Eledon Pharmaceuticals, Inc. ELDN | Logos Global Management LP | 0 0% | -1,339,793 (Position Closed) | View |
| 2022-01-10 5:57 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | BIOTECHNOLOGY VALUE FUND L P | 1,448,020 10.1% | 13,088 (+0.91%) | View |
| 2022-01-10 5:51 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | BIOTECHNOLOGY VALUE FUND L P | 1,434,932 9.99% | 1,434,932 (New Position) | View |
| 2021-09-09 12:30 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | Logos Global Management LP | 1,339,793 9.4% | 1,339,793 (New Position) | View |
| 2021-02-16 4:35 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | Woodline Partners LP | 814,756 5.4% | 814,756 (New Position) | View |
| 2021-02-16 4:17 pm Sale | 13G | Eledon Pharmaceuticals, Inc. ELDN | BIOTECHNOLOGY VALUE FUND L P | 1,503,121 9.99% | -14,918 (-0.98%) | View |
| 2021-02-16 3:14 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | 683 Capital Management, LLC | 35,900 1% | 35,900 (New Position) | View |
| 2021-02-08 10:29 am Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | FMR LLC | 1,004,111 6.623% | 1,004,111 (New Position) | View |
| 2021-01-05 4:38 pm Unchanged | 13D | Eledon Pharmaceuticals, Inc. ELDN | OrbiMed Israel BioFund GP Limited Partnership | 73,650 0.5% | 0 (Unchanged) | View |
| 2021-01-04 4:06 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | ADAGE CAPITAL PARTNERS GP, L.L.C. | 892,555 5.89% | 892,555 (New Position) | View |
| 2021-01-04 4:01 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | Cormorant Asset Management, LP | 1,415,500 9.89% | 1,415,500 (New Position) | View |
| 2020-12-30 5:27 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | BIOTECHNOLOGY VALUE FUND L P | 1,518,039 10% | 3,520 (+0.23%) | View |
| 2020-12-28 5:13 pm Purchase | 13G | Eledon Pharmaceuticals, Inc. ELDN | BIOTECHNOLOGY VALUE FUND L P | 1,514,519 9.99% | 1,319,193 (+675.38%) | View |
| 2020-12-04 5:12 pm Sale | 13D | Eledon Pharmaceuticals, Inc. ELDN | OrbiMed Israel BioFund GP Limited Partnership | 73,650 5.1% | -103,200 (-58.35%) | View |
| 2020-11-20 4:39 pm Unchanged | 13D | Eledon Pharmaceuticals, Inc. ELDN | OrbiMed Israel BioFund GP Limited Partnership | 176,850 12.4% | 0 (Unchanged) | View |